

This is a numerical listing by Presentation Number of the commercial relationship(s) and names of firm(s) with which commercial relationship(s) exists for each First Author and Co-Author as indicated at the time of abstract submission. First Authors or Co-Authors who indicated "None" for commercial relationship at the time of submission are not included on this Index.

Category Code Specific Financial Interests

Financial Support **F** indicates if you have received through your employing institution support from a for-profit company, or competing company, in the form of research funding or research materials or services (e.g. protein sequencing) at no cost, such support being the subject matter of your presentation or publication.

Personal Financial Interest **I** indicates if you are an investor in a company or competing company, other than through a mutual or retirement fund, which provides a product, service, process or equipment which is the subject matter of your presentation or publication.

E indicates if you are an employee of a company or competing company with a business interest, which is the subject matter of your presentation or publication.

C indicates if you are, or have been within the last three years, a consultant for a company or competing company with a business interest, which is the subject matter of your presentation or publication.

P indicates if you are an inventor/developer designated on a patent, patent application, copyright, or trade secret, whether or not the patent, copyright, etc. is presently licensed or otherwise commercialized, which is the subject matter of your presentation or publication or could be in competition with the technology described.

R indicates if you have received gifts in kind, honoraria or travel reimbursement valued at over \$1000 in the last twelve months from a company or competing company which provides a product, service, process or equipment which is the subject matter of your presentation or publication.

| | |
|--|--|
| P2.1 P.T. Khaw, Cambridge Antibody Technology; DanioLabs Ltd. | S7.9 P.T. Khaw, Cambridge Antibody Technology; DanioLabs; Preventing of scarring by MMP modulation; CibaVision Lecturer Japan 2006. |
| P2.2 M. Schwartz, Allergan, Proneuron Biotechnology Ltd. | S7.13 B.C. Chauhan, Carl Zeiss Meditec; Heidelberg Engineering. |
| P3.2 R. Allikmets, P. | S8.1 T.Y. Wong, Pfizer and Novartis; Pfizer and Novartis. |
| S2.3 E. Kim, 050554 (grant of the Korea Health 21 R&D project), F. | S8.12 J. Ambati, Quark Biotech; Quark Biotech. |
| S2.4 M.T. Coroneo, Inventor on patent applications in this area, P. | S8.16 J.B. Jonas, Member of the Allergan Posurdex Advisory Board. |
| S4.2 S. Norrby, E. | S9.4 W. Chan, Bausch & Lomb, F ; Bausch & Lomb, C ; Bausch & Lomb, R. |
| S4.8 W.E. Hill, Carl Zeiss Meditec; Alcon Laboratories; Santen; Carl Zeiss Meditec; Alcon Laboratories. | S9.8 J.F. Bille, 20/10 Perfect Vision GmbH, C - Currently, or within the last three years, been a consultant for a company or competing company with a business interest which is the subject matter of presentation. |
| S5.3 P.J. Foster, Carl Zeiss (UK), R ; Heidelberg Engineering, R. | S9.10 D.T. Tan, F, F. |
| S6.4 S. Kinoshita, ArBlast Co. Ltd. | S9.11 D. Huang, Carl Zeiss Meditec, Inc.; Optovue, Inc.; Optovue, Inc.; Carl Zeiss Meditec, Inc.. |
| S7.2 M. Schwartz, Allergan, Proneuron Biotechnology Ltd. | S10.1 R. Caspi, P - co-inventor on a patent application. |
| S7.7 M. Belkin, Consultant to Ellex. | S10.2 M. Schwartz, Allergan, Proneuron Biotechnology Ltd. |
| S7.8 H. Tanihara, Senju Pharmaceutical Com., Ltd., Japan. | S10.3 M.J. Young, SERI, P. |

- S12.2
J. Ambati, University of Kentucky.
- S13.2
H.J. Klassen, P.
- S13.6
S.J. Abraham, None; L. Farzana, None; S. Manjunath, None; A.K. Sheriff, None; J. Sudhakar, None; C.A.N. Jesudasan, None; P.A. Thomas, None; H. Yoshioka, Mebiol Inc, I; Y. Mori, Mebiol Inc, I; S. Amano, None.
- S13.10
K. Nishida, Cell Seed; Cell Seed.
- S14.1
B.C. Chauhan, Alcon Laboratories; Carl Zeiss Meditech; Heidelberg Engineering; Pfizer Ophthalmics; Welch Allyn.
- S14.6
D. Huang, Carl Zeiss Meditec, Inc.; Optovue, Inc.; Optovue, Inc.; Carl Zeiss Meditec, Inc.; Optovue, Inc.
- S14.7
S.D. Smith, Carl Zeiss Meditec, F.
- S14.8
K. Kashiwagi, Japanese patent.
- S14.10
J.F. Bille, Heidelberg Engineering GmbH, C.
- 12
B.D. Kuppermann, Allergan, Inc, C; G.A. Williams, Allergan, Inc, C; M.S. Blumenkranz, Allergan, Inc, C; P. Dugal, Allergan, Inc, C; J.A. Haller, Allergan, Inc, C; D.V. Weinberg, None; C. Chou, Allergan, Inc, E; S.M. Whitcup, Allergan, Inc, E.
- 13
I.G. Obrosova, None; J. Shin, None; V.R. Drel, None; V.R. Drel, None; W. Xu, E, E; J. Zhang, E., E; T.K. Ali, None; U. Julius, None; A. El-Remezzy, None.
- 19
L. Raghavan, None; K. Kashiwagi, Japanese patent application no – 2003-111322., P; T. Aung, None.
- 71
E. Borasio, Company not defined yet, P; J.D. Stevens, None; G.T. Smith, None.
- 116
J. Ku, Unrestricted grant and study IOLs provided by Alcon, R; N. Kerr, None; R. Johnson, None; G.D. Gamble, None; C.N.J. McGhee, None.
- 206
S. Yong, None; E. Goh, None; T. Lim, Invited speaker at 5th HRA Symposium, Kyoto, Japan, R.
- 208
K.K. Peh, None; Y.H. Tham, None; C.M.G. Cheung, None; Y.C. Yang, Travel grant: Pfizer; Research Grant: Genentech; Honoraria: Novartis., R.
- 214
V. Rajadhyaksha, Pfizer Inc, E.
- 221
A. Gupta, None; C.R. Gonzales, None; A.E. Kreiger, None; S.D. Schwartz, Optos, C.
- 226
J.A. Burke, Allergan, Inc., E; T. Lin, Allergan, Inc., E; K. Zhang, Allergan, Inc., E; W. Orilla, Allergan, Inc., E; C. Spada, Allergan, Inc., E; M. Escobar, Allergan, Inc., E; C. Ghosn, Allergan, Inc., E; L. Wheeler, Allergan, Inc., E.
- 230
M. Hossain, Pfizer Inc, E.
- 240
J.A. Burke, Allergan, Inc., E; C. Ghosn, Allergan, Inc., E; Y. Li, Allergan, Inc., E; W. Orilla, Allergan, Inc., E; T. Lin, Allergan, Inc., E; N. Linke, Allergan, Inc., E; B. DeBrosse, Allergan, Inc., E; M. Robinson, Allergan, Inc., E; L. Wheeler, Allergan, Inc., E.
- 254
J.T. Eells, Medical College of Wisconsin, P.
- 316
M. Singh, None; T. Aung, Carl Zeiss Meditec, R; D.S. Friedman, Carl Zeiss Meditec, C; C. Ze, None; P.J. Foster, None; W.P. Nolan, None; J.L. See, Carl Zeiss Meditec, R; S.D. Smith, Carl Zeiss Meditec, R; P.T.K. Chew, None.
- 330
K.K. Peh, None; R. Gupta, None; M.A.R. Awan, None; Y.C. Yang, Travel grant: Pfizer; Research Grant: Genentech; Honoraria: Novartis., R.
- 344
S. Norrby, AMO Groningen BV, E.
- 347
E.J. Seow, Essilor, E; B. Drobe, Essilor, E; F.L. Tang, Essilor, F.
- 348
B. Drobe, Essilor, E; E.J. Seow, Essilor, E; F.L. Tang, Essilor, F.
- 363
C. Lakkis, Alcon Research, Ltd, F; M. Boyd, Alcon Research, Ltd, F.
- 364
D. Meadows, Alcon Research, Ltd., E; R. Stone, Alcon Research, Ltd., C; L.D. Napier, Alcon Research, Ltd., E; H. Ketelson, Alcon Research, Ltd., E; D. Keith, Alcon Research, Ltd., E; R. Garofalo, Alcon Research, Ltd., E; J.R. Kern, Alcon Research, Ltd.
- 365
G.J. Andrasko, Alcon Research, Ltd., F; K. Ryen, Alcon Research, Ltd, F.
- 366
J.D. Choo, None; P.J. Caroline, Paragon Vision Sciences, R; E.B. Papas, None; M. Willcox, None; B.A. Holden, None.
- 367
C.H. Powell, Advanced Medical Optics, E; S.W. Huth, Advanced Medical Optics, E; L.D. Hoong, Advanced Medical Optics, E; K. Ambrus, Advanced Medical Optics, E.

- 369
R. Yanai, None; Y. Ishida, None; K. Ueda, None; T. Nishida, None; O. Mori, Menicon, E.
- 371
K. Tan, CooperVision, Inc., E.
- 378
G. Sitalakshmi, None; H.N. Madhavan, None; B. Sudha, None; S. Krishnakumar, None; V.S. Pillai, None; Y. Mori, P, P; H. Yoshioka, P, P; S. Abraham, E, E.
- 465
P. van Sarloos, CEO, I; T. Pujara, Employee, E; J. Rodger, None; T. Sanders, None.
- 485
M.C. Boucher, Laboratoires de la rétine RD, I; G. Desroches, None; R. Garcia, None; A. Kherani, None; D. Maberley, None; M. Oh, None; S. Olivier, None; M. Potter, None; F. Stockl, None; A. Vachon, None.
- 497
A.C.S. Tan, Scan Optics, F; Christian Blind Mission, R; R. Le Mesurier, None; H. Newland, None.
- 503
K. Tan, CooperVision, Inc., E.
- 508
C. Ng, None; W. Tang, None; D. Tan, None; N. Ellenbogen, Neurovision, E.
- 521
A.P. Ginsburg, Vision Sciences Research Corp, F; VSRC, I; VSRC, E; Stereo Optical Co, C; VSRC, P; Stereo Optical Co, R.
- 525
J.L. Yang, None; J. Schachter, Gen-Probe, F; Roche, F; J. Moncada, None; W. Alemayehu, None; T. Lekew, None; J.I. House, None; K.C. Hong, None; M.D. Neuwelt, None; Z. Zhou, None; T.M. Lietman, None.
- 607
C.N. Ta, Allergan, C; Allergan, R; L. Shahinian, Jr., None.
- 618
M.G. Daroy, None; J.S. Lopez, None; B.C.L. Torres, None; V. Oh, None; M. Loy, None; R. LimBonSiong, None; P.C. Tuano, None; R.R. Matias, United Laboratories Inc., F; F.F. Natividad, None.
- 621
M.E. Stern, Allergan, Inc., E; J.Y. Niederkorn, Allergan, Inc., C; K.F. Siemasko, Allergan, Inc., E; J. Gao, Allergan, Inc., E; M. Calonge, Allergan, Inc., C; V.L. Calder, Allergan, Inc., C; S.C. Pflugfelder, Allergan, Inc., C.

